Innovation Pharmaceuticals Inc (IPIX)

[FlashingLeather]

The scientific skepticism on previous CTIX data has been whether K actually does modulate p53. The intent of the current K-OC trial, in combination with related murine studies, is to unequivocally prove that K modulates p53 in a productive manner, as Dr. B has stated.

If they're able to accomplish that to the satisfaction of BP entities who no-doubt contributed to the trial design, a partnership will ensue.

Evidently it is important to big Pharma not only to have the first approved P53 modulating drug but also know its exact MOA.